AU2017238651B2 - Formulation of antibody molecules to dengue virus - Google Patents

Formulation of antibody molecules to dengue virus Download PDF

Info

Publication number
AU2017238651B2
AU2017238651B2 AU2017238651A AU2017238651A AU2017238651B2 AU 2017238651 B2 AU2017238651 B2 AU 2017238651B2 AU 2017238651 A AU2017238651 A AU 2017238651A AU 2017238651 A AU2017238651 A AU 2017238651A AU 2017238651 B2 AU2017238651 B2 AU 2017238651B2
Authority
AU
Australia
Prior art keywords
formulation
antibody molecule
amino acid
acid sequence
antibody
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
AU2017238651A
Other languages
English (en)
Other versions
AU2017238651A1 (en
Inventor
Catherine HAY
Susan Sloan
Bi XU
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Visterra Inc
Original Assignee
Visterra Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Visterra Inc filed Critical Visterra Inc
Publication of AU2017238651A1 publication Critical patent/AU2017238651A1/en
Application granted granted Critical
Publication of AU2017238651B2 publication Critical patent/AU2017238651B2/en
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A61K39/39591—Stabilisation, fragmentation
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A61K39/42—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum viral
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/02—Inorganic compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
    • A61K47/12—Carboxylic acids; Salts or anhydrides thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/16—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing nitrogen, e.g. nitro-, nitroso-, azo-compounds, nitriles, cyanates
    • A61K47/18—Amines; Amides; Ureas; Quaternary ammonium compounds; Amino acids; Oligopeptides having up to five amino acids
    • A61K47/183—Amino acids, e.g. glycine, EDTA or aspartame
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/22—Heterocyclic compounds, e.g. ascorbic acid, tocopherol or pyrrolidones
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/26—Carbohydrates, e.g. sugar alcohols, amino sugars, nucleic acids, mono-, di- or oligo-saccharides; Derivatives thereof, e.g. polysorbates, sorbitan fatty acid esters or glycyrrhizin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/08—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from viruses
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/08—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from viruses
    • C07K16/10—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from viruses from RNA viruses
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2851—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the lectin superfamily, e.g. CD23, CD72
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C07K2317/565—Complementarity determining region [CDR]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
    • C07K2317/94—Stability, e.g. half-life, pH, temperature or enzyme-resistance
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2770/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses positive-sense
    • C12N2770/00011—Details
    • C12N2770/24011—Flaviviridae
    • C12N2770/24111—Flavivirus, e.g. yellow fever virus, dengue, JEV
    • C12N2770/24121—Viruses as such, e.g. new isolates, mutants or their genomic sequences
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
    • Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
    • Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Immunology (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Virology (AREA)
  • Molecular Biology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Biochemistry (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Genetics & Genomics (AREA)
  • Biophysics (AREA)
  • Oil, Petroleum & Natural Gas (AREA)
  • Mycology (AREA)
  • Microbiology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Inorganic Chemistry (AREA)
  • Communicable Diseases (AREA)
  • Oncology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Medicinal Preparation (AREA)
  • Peptides Or Proteins (AREA)
AU2017238651A 2016-03-25 2017-03-24 Formulation of antibody molecules to dengue virus Active AU2017238651B2 (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201662313558P 2016-03-25 2016-03-25
US62/313,558 2016-03-25
PCT/US2017/023973 WO2017165736A1 (en) 2016-03-25 2017-03-24 Formulation of antibody molecules to dengue virus

Publications (2)

Publication Number Publication Date
AU2017238651A1 AU2017238651A1 (en) 2018-10-04
AU2017238651B2 true AU2017238651B2 (en) 2024-06-13

Family

ID=58489109

Family Applications (1)

Application Number Title Priority Date Filing Date
AU2017238651A Active AU2017238651B2 (en) 2016-03-25 2017-03-24 Formulation of antibody molecules to dengue virus

Country Status (8)

Country Link
US (3) US20170274076A1 (enExample)
EP (1) EP3433274A1 (enExample)
JP (2) JP7155009B2 (enExample)
CN (1) CN109311986A (enExample)
AU (1) AU2017238651B2 (enExample)
CA (1) CA3018216A1 (enExample)
TW (2) TW202302144A (enExample)
WO (1) WO2017165736A1 (enExample)

Families Citing this family (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU2015217572B2 (en) 2014-02-11 2020-10-15 Visterra, Inc. Antibody moleules to dengue virus and uses thereof
CA3018216A1 (en) 2016-03-25 2017-09-28 Visterra, Inc. Formulations of antibody molecules to dengue virus
DK3559027T3 (da) * 2016-12-23 2022-09-05 Serum Institute Of India Pvt Ltd Fremgangsmåder til forbedring af antistofoproduktivitet i pattedyrecellekultur og minimering af aggregering nedstrøms, formuleringsprocesser og stabile antistofformuleringer opnået deraf
PE20210654A1 (es) 2017-12-07 2021-03-31 Merck Sharp & Dohme Formulaciones de composiciones de vacuna contra el virus del dengue
CN120241997A (zh) 2019-02-18 2025-07-04 伊莱利利公司 治疗性抗体制剂
CN109856383B (zh) * 2019-03-05 2022-04-15 肖国林 一种用于宫颈癌辅助诊断的免疫化学染色试剂盒
EP3965820A4 (en) * 2019-05-07 2023-02-08 The Regents of the University of California COMPOSITIONS AND METHODS TO PROMOTE HEALTHY NEURAL DEVELOPMENT IN AN UNBORN BABY
WO2020264011A1 (en) * 2019-06-24 2020-12-30 Lai Jonathan R Resurfaced dengue virus and ziki virus glycoprotein e diii variants and uses thereof
WO2021021837A2 (en) * 2019-07-29 2021-02-04 Compugen Ltd. Anti-pvrig antibodies formulations and uses thereof
EP4139352A1 (en) * 2020-04-22 2023-03-01 Chemomab Ltd. Method of treatment using anti-ccl24 antibody
WO2022000046A1 (en) * 2020-07-03 2022-01-06 CSL Innovation Pty Ltd High concentration formulation of factor xii antigen binding proteins

Family Cites Families (54)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4816567A (en) 1983-04-08 1989-03-28 Genentech, Inc. Recombinant immunoglobin preparations
JPS6147500A (ja) 1984-08-15 1986-03-07 Res Dev Corp Of Japan キメラモノクロ−ナル抗体及びその製造法
EP0173494A3 (en) 1984-08-27 1987-11-25 The Board Of Trustees Of The Leland Stanford Junior University Chimeric receptors by dna splicing and expression
GB8422238D0 (en) 1984-09-03 1984-10-10 Neuberger M S Chimeric proteins
JPS61134325A (ja) 1984-12-04 1986-06-21 Teijin Ltd ハイブリツド抗体遺伝子の発現方法
GB8607679D0 (en) 1986-03-27 1986-04-30 Winter G P Recombinant dna product
US5225539A (en) 1986-03-27 1993-07-06 Medical Research Council Recombinant altered antibodies and methods of making altered antibodies
DE3883899T3 (de) 1987-03-18 1999-04-22 Sb2, Inc., Danville, Calif. Geänderte antikörper.
US5223409A (en) 1988-09-02 1993-06-29 Protein Engineering Corp. Directed evolution of novel binding proteins
DE768377T1 (de) 1988-09-02 1998-01-02 Dyax Corp Herstellung und Auswahl von Rekombinantproteinen mit verschiedenen Bindestellen
US5530101A (en) 1988-12-28 1996-06-25 Protein Design Labs, Inc. Humanized immunoglobulins
GB8905669D0 (en) 1989-03-13 1989-04-26 Celltech Ltd Modified antibodies
WO1991000906A1 (en) 1989-07-12 1991-01-24 Genetics Institute, Inc. Chimeric and transgenic animals capable of producing human antibodies
ATE139258T1 (de) 1990-01-12 1996-06-15 Cell Genesys Inc Erzeugung xenogener antikörper
US5427908A (en) 1990-05-01 1995-06-27 Affymax Technologies N.V. Recombinant library screening methods
DK0585287T3 (da) 1990-07-10 2000-04-17 Cambridge Antibody Tech Fremgangsmåde til fremstilling af specifikke bindingsparelementer
GB9015198D0 (en) 1990-07-10 1990-08-29 Brien Caroline J O Binding substance
AU664976B2 (en) 1990-08-29 1995-12-14 Gene Pharming Europe Bv Homologous recombination in mammalian cells
AU8507191A (en) 1990-08-29 1992-03-30 Genpharm International, Inc. Transgenic non-human animals capable of producing heterologous antibodies
CA2095633C (en) 1990-12-03 2003-02-04 Lisa J. Garrard Enrichment method for variant proteins with altered binding properties
ES2287206T3 (es) 1991-03-01 2007-12-16 Dyax Corporation Proceso para el desarrollo de mini-proteinas de union.
WO1992018619A1 (en) 1991-04-10 1992-10-29 The Scripps Research Institute Heterodimeric receptor libraries using phagemids
DE69233482T2 (de) 1991-05-17 2006-01-12 Merck & Co., Inc. Verfahren zur Verminderung der Immunogenität der variablen Antikörperdomänen
DE4122599C2 (de) 1991-07-08 1993-11-11 Deutsches Krebsforsch Phagemid zum Screenen von Antikörpern
DE69330523D1 (de) 1992-08-21 2001-09-06 Vrije Universiteit Brussel Bru Immunoglobuline ohne leichte ketten
ES2523168T3 (es) 2001-05-22 2014-11-21 The Government Of The United States Of America As Represented By The Secretary Of The Department Of Health And Human Services Desarrollo de mutaciones útiles para atenuar virus del dengue y virus del dengue quiméricos
US7232888B2 (en) 2002-07-01 2007-06-19 Massachusetts Institute Of Technology Antibodies against tumor surface antigens
US7473424B2 (en) 2003-01-31 2009-01-06 The Scripps Research Institute Anti-dengue virus antibodies and compositions
CA2548808C (en) 2003-12-08 2015-07-07 The Government Of The United States Of America, As Represented By The Secretary, Department Of Health And Human Services Monoclonal antibodies that bind or neutralize dengue virus
AU2006245734C1 (en) 2005-05-12 2012-05-24 Crucell Holland B.V. Host cell specific binding molecules capable of neutralizing viruses and uses thereof
US7943134B2 (en) 2005-08-31 2011-05-17 Academia Sinica Compositions and methods for identifying response targets and treating flavivirus infection responses
CU23586A1 (es) 2005-11-22 2010-10-30 Ct Ingenieria Genetica Biotech Métodos y proteínas para el tratamiento profiláctico y/o terapéutico de los cuatro serotipos del virus de dengue y otros flavivirus
CU23632A1 (es) 2006-04-28 2011-02-24 Ct Ingenieria Genetica Biotech Métodos para la identificación de candidatos terapéuticos contra enfermedades causadas por flavivirus y moléculas antivirales.
EP2144931A2 (en) 2007-04-04 2010-01-20 The Government Of The U.S.A, As Represented By The Secretary, Dept. Of Health And Human Services Monoclonal antibodies against dengue and other viruses with deletion in fc region
US20100150912A1 (en) 2007-04-11 2010-06-17 Novartis Ag Blocking interaction between pathogen factors and factor h to inhibit hemorrhagic syndromes
JP5814790B2 (ja) 2008-10-13 2015-11-17 インスティテュート・フォー・リサーチ・イン・バイオメディシンＩｎｓｔｉｔｕｔｅ Ｆｏｒ Ｒｅｓｅａｒｃｈ Ｉｎ Ｂｉｏｍｅｄｉｃｉｎｅ デングウイルス中和抗体およびその使用
SG173482A1 (en) 2009-02-10 2011-09-29 Univ Nanyang Tech Antibodies for diagnosis and treatment of flaviviral infections
AU2010221156A1 (en) 2009-03-06 2011-09-22 Genentech, Inc. Antibody formulation
US20110059079A1 (en) 2009-09-04 2011-03-10 Xoma Technology Ltd. Antibody Coformulations
IT1395574B1 (it) 2009-09-14 2012-10-16 Guala Dispensing Spa Dispositivo di erogazione
EP2519262A2 (en) * 2009-12-29 2012-11-07 F. Hoffmann-La Roche AG Antibody formulation
US8637035B2 (en) 2010-07-16 2014-01-28 Academia Sinica Anti-dengue virus antibodies
AU2011341744B2 (en) 2010-12-14 2016-09-08 Dso National Laboratories Human monoclonal antibody with specificity for dengue virus serotype 1 E protein and uses thereof
AU2012305807B2 (en) 2011-09-09 2015-08-20 Department of Medical Sciences (DMSc) Dengue-virus serotype neutralizing antibodies
US20140349321A1 (en) 2011-12-16 2014-11-27 Agency For Science, Technology And Research Binding molecules against dengue virus and uses thereof
US8920804B2 (en) 2011-12-22 2014-12-30 Inbios International, Inc. Methods and materials for the detection of dengue virus infection
BR112014024612A2 (pt) 2012-04-02 2021-06-08 Univ North Carolina Chapel Hill ácido nucleico, polipeptídeo, glicoproteína e quimérica, epítopo de vírus da dengue, partícula semelhante a flavivírus quimérico (vlp), flavivírus quimérico, e métodos in vitro para identificar um anticorpo neutralizante e para identificar uma composição imunogênica contra um vírus da dengue
US9556254B2 (en) 2012-05-14 2017-01-31 The Usa, As Represented By The Secretary, Dept. Of Health And Human Services Cross-reactive antibodies against dengue virus and uses thereof
JP6297560B2 (ja) 2012-08-07 2018-03-20 マサチューセッツ インスティテュート オブ テクノロジー 抗デングウイルス抗体およびその使用
WO2014110092A1 (en) 2013-01-08 2014-07-17 Humabs Biomed Sa Methods of generating robust passive and active immune responses
CN105051064A (zh) * 2013-01-24 2015-11-11 葛兰素史克知识产权开发有限公司 抗TNF-α抗原结合蛋白
AU2015217572B2 (en) 2014-02-11 2020-10-15 Visterra, Inc. Antibody moleules to dengue virus and uses thereof
CN106413749B (zh) 2014-02-11 2022-04-05 麻省理工学院 新颖全谱抗登革抗体
CA3018216A1 (en) 2016-03-25 2017-09-28 Visterra, Inc. Formulations of antibody molecules to dengue virus

Also Published As

Publication number Publication date
CN109311986A (zh) 2019-02-05
US20200237913A1 (en) 2020-07-30
US20170274076A1 (en) 2017-09-28
CA3018216A1 (en) 2017-09-28
TW201735948A (zh) 2017-10-16
TWI763660B (zh) 2022-05-11
EP3433274A1 (en) 2019-01-30
AU2017238651A1 (en) 2018-10-04
US11918651B2 (en) 2024-03-05
WO2017165736A1 (en) 2017-09-28
TW202302144A (zh) 2023-01-16
JP7155009B2 (ja) 2022-10-18
JP2019509311A (ja) 2019-04-04
US20240366758A1 (en) 2024-11-07
JP2022172100A (ja) 2022-11-15

Similar Documents

Publication Publication Date Title
AU2017238651B2 (en) Formulation of antibody molecules to dengue virus
US12054539B2 (en) Antibody molecules to dengue virus and uses thereof
AU2016340989B2 (en) Anti-IL-2 antibodies and compositions and uses thereof
AU2018292618A1 (en) Dosage regimens for anti-TIM-3 antibodies and uses thereof
AU2015315063A1 (en) Methods of treating autoimmune disease using a domain antibody directed against CD40L
RU2804775C2 (ru) Режимы дозирования для антител против tim-3 и их применения
HK40079325A (en) Antibody molecules to dengue virus and uses thereof
HK40078924A (en) Anti-cd30 antibody-drug conjugates and their use for the treatment of hiv infection
BR122024007318A2 (pt) Moléculas de anticorpo para vírus da dengue e suas utilizações
HK1232551B (en) Antibody moleules to dengue virus and uses thereof

Legal Events

Date Code Title Description
FGA Letters patent sealed or granted (standard patent)